- Home
- ADUR vs DMAC Comparison
ADUR vs DMAC Comparison
Compare ADUR & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUR
- DMAC
- Stock Information
- Founded
- ADUR 2011
- DMAC 2000
- Country
- ADUR Canada
- DMAC United States
- Employees
- ADUR N/A
- DMAC N/A
- Industry
- ADUR
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ADUR
- DMAC Health Care
- Exchange
- ADUR NYSE
- DMAC Nasdaq
- Market Cap
- ADUR 154.9M
- DMAC 172.7M
- IPO Year
- ADUR N/A
- DMAC N/A
- Fundamental
- Price
- ADUR $5.50
- DMAC $4.70
- Analyst Decision
- ADUR
- DMAC Strong Buy
- Analyst Count
- ADUR 0
- DMAC 3
- Target Price
- ADUR N/A
- DMAC $7.00
- AVG Volume (30 Days)
- ADUR 126.5K
- DMAC 105.5K
- Earning Date
- ADUR 01-01-0001
- DMAC 11-13-2024
- Dividend Yield
- ADUR N/A
- DMAC N/A
- EPS Growth
- ADUR N/A
- DMAC N/A
- EPS
- ADUR N/A
- DMAC N/A
- Revenue
- ADUR $247,485.00
- DMAC N/A
- Revenue This Year
- ADUR N/A
- DMAC N/A
- Revenue Next Year
- ADUR N/A
- DMAC N/A
- P/E Ratio
- ADUR N/A
- DMAC N/A
- Revenue Growth
- ADUR 98.59
- DMAC N/A
- 52 Week Low
- ADUR $1.34
- DMAC $2.14
- 52 Week High
- ADUR $7.00
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- ADUR N/A
- DMAC 63.73
- Support Level
- ADUR N/A
- DMAC $3.96
- Resistance Level
- ADUR N/A
- DMAC $4.21
- Average True Range (ATR)
- ADUR 0.00
- DMAC 0.21
- MACD
- ADUR 0.00
- DMAC 0.02
- Stochastic Oscillator
- ADUR 0.00
- DMAC 87.64
About ADUR ADURO CLEAN TECHNOLOGIES INC
Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.